The Institute for Clinical and Economic Review (ICER) has posted the final report CardioMEMS™ HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto™, Novartis AG) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks and accompanying materials to the California Technology Assessment Forum (CTAF) website. The report evaluates the comparative effectiveness and value of the CardioMEMS device, a system that monitors increases in pulmonary artery pressure (an indicator of worsening congestive heart failure, or CHF), and the drug Entresto, which is a combination of an angiotensin II receptor blocker (ARB) and neprilysin inhibitor.
Providing credible, evidence-based information about medical technologies, treatments, and models of care
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), reviews objective evidence reports and holds public meetings to develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care.
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.